Date: November 12, 2026
Board Meeting Outcomes
The company submits a correction to the outcome of the Board of Directors meeting held on October 22, 2026, which had approved the conversion of the entire outstanding debt including service cost aggregating up to ₹57.00 crore extended by the Company to its material subsidiary Kilitch Estro Biotech PLC (KEB) into equity shares of KEB.
Correction Details
Due to a typographical error in the original submission:
- The number of equity shares of KEB to be allotted to the Company was incorrectly stated as 1,66,472 shares instead of the correct number of 1,66,471 shares
- The acquisition price was incorrectly stated as ₹3,414 per share instead of the correct price of ₹3,413.23 per share
Modified Points
Point No. 8 (Cost of Acquisition and the price at which the shares are acquired) and Point No. 9 (Percentage of shareholding/control acquired and/or number of shares acquired) of Annexure B to the Board Meeting outcome dated October 22, 2026, are modified to reflect:
- Rectified acquisition price: ₹3,413.23 (Rupees Three Thousand Four Hundred and Thirteen and Twenty-Three Paise only) per equity share
- Rectified number of shares: 1,66,471 (One Lakh Sixty-Six Thousand Four Hundred and Seventy-One) equity shares
Status of Original Approval
Except for this rectification and consequential changes, all other terms and conditions of the proposed conversion as approved by the Board remain unchanged.